Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease (Q45254399)

11 December 2017

Comparison of the efficacy of rotavirus VLP vaccines to a live homologous rotavirus vaccine in a pig model of rotavirus disease (English)

1 reference

11 December 2017

1 reference

5

1 reference

11 December 2017

L El-Attar

1

1 reference

11 December 2017

S L Oliver

2

1 reference

11 December 2017

A Mackie

3

1 reference

11 December 2017

A Charpilienne

4

1 reference

11 December 2017

J Cohen

6

1 reference

11 December 2017

J C Bridger

7

1 reference

11 December 2017

language of work or name

English

0 references

publication date

7 April 2009

1 reference

11 December 2017

1 reference

11 December 2017

27

1 reference

11 December 2017

24

1 reference

11 December 2017

3201-3208

1 reference

Current status and future priorities for rotavirus vaccine development, evaluation and implementation in developing countries

11 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Global Illness and Deaths Caused by Rotavirus Disease in Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Rotavirus and severe childhood diarrhea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Rotavirus vaccines: current prospects and future challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

A VP4 sequence highly conserved in human rotavirus strain AU-1 and feline rotavirus strain FRV-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Full genomic analysis of human rotavirus strain B4106 and lapine rotavirus strain 30/96 provides evidence for interspecies transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Human rotavirus strain with unique VP4 neutralization epitopes as a result of natural reassortment between members of the AU-1 and Wa genogroups

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Molecular characterization of novel G5 bovine rotavirus strains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Magnitude of serum and intestinal antibody responses induced by sequential replicating and nonreplicating rotavirus vaccines in gnotobiotic pigs and correlation with protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Host, viral, and vaccine factors that determine protective efficacy induced by rotavirus and virus-like particles (VLPs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Individual rotavirus-like particles containing 120 molecules of fluorescent protein are visible in living cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Antibody responses to human rotavirus (HRV) in gnotobiotic pigs following a new prime/boost vaccine strategy using oral attenuated HRV priming and intranasal VP2/6 rotavirus-like particle (VLP) boosting with ISCOM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Heterotypic protection from rotavirus infection in mice vaccinated with virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Protection and antibody responses to oral priming by attenuated human rotavirus followed by oral boosting with 2/6-rotavirus-like particles with immunostimulating complexes in gnotobiotic pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Intranasal administration of 2/6-rotavirus-like particles with mutant Escherichia coli heat-labile toxin (LT-R192G) induces antibody-secreting cell responses but not protective immunity in gnotobiotic pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Parenteral administration of RF 8-2/6/7 rotavirus-like particles in a one-dose regimen induce protective immunity in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Vaccinia—rotavirus VP7 recombinants protect mice against rotavirus-induced diarrhoea

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

The pathogenicity of two porcine rotaviruses differing in their in vitro growth characteristics and genes 4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Amount of maternal rotavirus-specific antibodies influence the outcome of rotavirus vaccination of newborn mice with virus-like particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Bone Marrow Dendritic Cells Internalize Live RF-81 Bovine Rotavirus and Rotavirus-like Particles (RF 2/6-GFP-VLP and RF 8*2/6/7-VLP) But are Only Activated by Live Bovine Rotavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Utility of SHIV for testing HIV-1 vaccine candidates in macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Antigenic and pathogenic relationships of three bovine rotaviruses and a porcine rotavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

The lesions of rotavirus infection in 1- and 10-day-old gnotobiotic calves.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Yeast expression of the VP8* fragment of the rotavirus spike protein and its use as immunogen in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

High-resolution molecular and antigen structure of the VP8* core of a sialic acid-independent human rotavirus strain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Avirulent rotavirus infections protect calves from disease with and without inducing high levels of neutralizing antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Cytokine responses in gnotobiotic pigs after infection with virulent or attenuated human rotavirus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Inactivated rotavirus vaccines: a priority for accelerated vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

Subunit rotavirus vaccine administered parenterally to rabbits induces active protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

7 January 2021

Rotavirus vaccine administered parenterally induces protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

7 January 2021

Immunodominance of the VP4 neutralization protein of rotavirus in protective natural infections of young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

7 January 2021

Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

7 January 2021

Antibody-independent protection against rotavirus infection of mice stimulated by intranasal immunization with chimeric VP4 or VP6 protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.03.043

7 January 2021

10.1016/J.VACCINE.2009.03.043

Identifiers

DOI

1 reference

11 December 2017

1 reference